Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...

While iterative developments have improved outcomes of patients with myocardial infarction, mortality in patients with acute ...

Cardiogenic dementia is a condition where heart disease can increase a person’s risk of cognitive problems. People with heart disease, chronic diseases of the cardiovascular system, and smokers ...

Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

Explore the latest innovations in cardiogenic shock treatment, including advances in mechanical circulatory support devices, ...

WARRINGTON, Pa. - Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology firm specializing in the development of therapies for critical diseases and currently valued at $1.44 million market ...

Are you searching for effective medications to treat 'Cardiogenic Shock'? This comprehensive guide provides the latest information on medications-both generic and branded-that are essential for ...

Safety and outcomes are improving at Seattle-based Swedish Heart & Vascular Institute thanks to two rapid response teams for high acuity issues: the cardiogenic shock team and the pulmonary ...

Windtree Therapeutics (WINT) announced that an istaroxime presentation featuring the positive Phase 2b SEISMiC study was given on February 11, ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Cardiogenic shock occurs when the heart is not able to pump enough blood to generate adequate cardiac output to maintain normal blood pressure. This frequently occurs in the setting of a large ...